Literature DB >> 31738925

Undisclosed payments by pharmaceutical and medical device manufacturers to authors of endoscopy guidelines in the United States.

Rishi Bansal1, Rishad Khan1, Michael A Scaffidi1, Nikko Gimpaya1, Shai Genis1, Abbas Bukhari1, Jeevan Dhillon1, Kathy Dao1, Chris Bonneau1, Samir C Grover2.   

Abstract

BACKGROUND AND AIMS: Payments from pharmaceutical and medical device manufacturers to authors of clinical practice guidelines (CPGs) may influence practice recommendations. It is therefore important to evaluate the completeness of financial conflict of interest (FCOI) declarations among CPG authors.
METHODS: We performed a cross-sectional analysis of industry payments to authors of endoscopy guidelines published by 5 GI societies between 2014 and 2017. For each author we identified payments using the disclosure section of CPGs and the Centers for Medicare & Medicaid Services Open Payments (CMS-OP) database. We calculated the prevalence, monetary value, and type of declared and undeclared payments among authors. Payments were assessed for the calendar year of and before publication.
RESULTS: Thirty-seven CPGs were included in the analysis comprising 569 author entries (91 unique individuals; 66.43% men, 92.6% physicians, 66.4% academically affiliated). Four hundred fifty-one episodes (79%) involved FCOIs, 451 (79%) had undisclosed FCOIs in the CMS-OP, and 445 (77%) had FCOIs relevant to a CPG recommendation. The median undisclosed payment value was $4807.26 (interquartile range, $334.84-$20,579.75). Male authors (odds ratio, 2.23; 95% confidence interval, 1.47-3.39) and academically affiliated authors (odds ratio, 8.87; 95% confidence interval, 5.57-14.13) were significantly more likely to have undeclared payments (P < .001). No CPGs met all National Academy of Medicine criteria.
CONCLUSIONS: Recognizing concerns about the accuracy of the CMS-OP, there are substantial discrepancies between industry-reported payments and author self-disclosure. Additionally, there is a high prevalence of undisclosed payments by pharmaceutical and medical device manufacturers to these authors. Given the potential impact of these discrepancies and undisclosed payments on CPGs, more accurate reporting and alternative strategies for managing FCOI are needed.
Copyright © 2020 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Mesh:

Year:  2019        PMID: 31738925     DOI: 10.1016/j.gie.2019.11.010

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  3 in total

1.  A cross-sectional examination of conflict-of-interest disclosures of physician-authors publishing in high-impact US medical journals.

Authors:  James H Baraldi; Steven A Picozzo; Jacob C Arnold; Kathryn Volarich; Michael R Gionfriddo; Brian J Piper
Journal:  BMJ Open       Date:  2022-04-11       Impact factor: 3.006

2.  Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States.

Authors:  Eman Al Sulais; Majid Alsahafi; Turki AlAmeel
Journal:  Saudi J Gastroenterol       Date:  2021 Nov-Dec       Impact factor: 2.485

3.  Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease.

Authors:  Karam Elsolh; Daniel Tham; Michael A Scaffidi; Nikko Gimpaya; Rishi Bansal; Nazi Torabi; Juana Li; Yash Verma; Rishad Khan; Samir C Grover
Journal:  J Can Assoc Gastroenterol       Date:  2022-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.